0JDK.LSE Iovance Biotherapeutics Inc.

Healthcare Commercial Services & Supplies London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
-34.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0JDK.LSE undervalued?

Graham number

The Graham number of Iovance Biotherapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Iovance Biotherapeutics Inc. fundamental analysis

No fundamental analysis for Iovance Biotherapeutics Inc. yet.

Iovance Biotherapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Iovance Biotherapeutics Inc.

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; …

Full company profile